Elevance Health (NYSE:ELV) Shares Down 5.8% After Earnings Miss

Shares of Elevance Health, Inc. (NYSE:ELV - Get Free Report) traded down 5.8% during mid-day trading on Friday following a dissappointing earnings announcement. The company traded as low as $285.00 and last traded at $285.03. 619,345 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 1,647,853 shares. The stock had previously closed at $302.45.

The company reported $8.84 earnings per share for the quarter, missing the consensus estimate of $9.30 by ($0.46). The business had revenue of $49.42 billion during the quarter, compared to the consensus estimate of $48.26 billion. Elevance Health had a return on equity of 18.61% and a net margin of 3.23%. The business's revenue was up 14.3% on a year-over-year basis. During the same period last year, the business posted $10.12 earnings per share.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th were paid a $1.71 dividend. The ex-dividend date of this dividend was Tuesday, June 10th. This represents a $6.84 annualized dividend and a dividend yield of 2.41%. Elevance Health's dividend payout ratio is presently 26.69%.

Analyst Ratings Changes

A number of research firms have issued reports on ELV. Baird R W downgraded Elevance Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 15th. Royal Bank Of Canada restated an "outperform" rating and issued a $478.00 target price on shares of Elevance Health in a research note on Wednesday, June 4th. Barclays cut their target price on Elevance Health from $480.00 to $434.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 9th. Leerink Partners reaffirmed a "market perform" rating and issued a $310.00 price target (down previously from $510.00) on shares of Elevance Health in a report on Friday. Finally, Mizuho boosted their target price on shares of Elevance Health from $455.00 to $505.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $456.44.

Insider Buying and Selling

In related news, CFO Mark Kaye sold 4,588 shares of the stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $424.82, for a total value of $1,949,074.16. Following the transaction, the chief financial officer owned 18,977 shares of the company's stock, valued at $8,061,809.14. This represents a 19.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.29% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ELV. Proficio Capital Partners LLC boosted its position in Elevance Health by 33.5% during the fourth quarter. Proficio Capital Partners LLC now owns 626 shares of the company's stock valued at $231,000 after buying an additional 157 shares during the period. Creative Financial Designs Inc. ADV boosted its position in Elevance Health by 21.4% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 676 shares of the company's stock valued at $249,000 after buying an additional 119 shares during the period. Axxcess Wealth Management LLC boosted its position in Elevance Health by 48.1% during the fourth quarter. Axxcess Wealth Management LLC now owns 1,509 shares of the company's stock valued at $557,000 after buying an additional 490 shares during the period. Advisors Asset Management Inc. boosted its position in Elevance Health by 54.1% during the fourth quarter. Advisors Asset Management Inc. now owns 12,912 shares of the company's stock valued at $4,763,000 after buying an additional 4,535 shares during the period. Finally, Horizon Investments LLC boosted its position in Elevance Health by 1.0% during the fourth quarter. Horizon Investments LLC now owns 3,852 shares of the company's stock valued at $1,421,000 after buying an additional 40 shares during the period. Institutional investors own 89.24% of the company's stock.

Elevance Health Trading Down 6.3%

The firm's 50-day simple moving average is $374.07 and its 200-day simple moving average is $396.26. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $64.00 billion, a PE ratio of 10.98, a price-to-earnings-growth ratio of 0.88 and a beta of 0.60.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.